

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

## COMPLETE VERSION OF ALL PENDING CLAIMS

### WHAT IS CLAIMED IS:

1. (Amended) A pharmaceutical composition for the treatment of sinusitis comprising a therapeutically effective amount of a peptide having a C-terminal sequence amino acid sequence KPV (SEQ ID NO:1) in combination with a therapeutically effective amount of a decongestant/antihistamine.
2. (Amended) The pharmaceutical composition of claim 1 wherein the peptide is selected from the group of peptides with a C-terminal amino acid sequence consisting of: KPV (SEQ ID NO:1), VPK-Ac-CC-Ac-KPV, HFRWGKPV (SEQ ID NO:2) and SYSMEHFRWGKPV (SEQ ID NO:3).
3. The composition of claim 1 wherein said decongestant/antihistamine is selected from the group consisting of: pseudoephedrine, phenylephrine, phenylpropanolamine, chlorpheniramine, brompheniramine, pheniramine and loratidine.
4. The composition of claim 1 further comprising a therapeutically effective amount of an antibiotic.
5. The composition of claim 4 wherein said antibiotic is selected from the group consisting of: amoxicillin, ampicillin, azithromycin, erythromycin, nafcillin, penicillin, amoxicillin/clavulanate potassium, cefuroxime axetil, cefpodoxime proxetil, clarithromycin, and azithromycin.

6. The composition of claim 1 further comprising a therapeutically effective amount of a glucocorticosteroid.
7. The composition of claim 6 wherein said glucocorticosteroid is selected from the group consisting of: betamethasone, budesponide, cortisone, dexamethasone, hydrocortisone, methylprednisone, prednisone, triamcinolone.
8. The composition of claim 1 further comprising a therapeutically effective amount of a fungicide.
9. The composition of claim 8 wherein said fungicide is selected from the group consisting of: itraconazole, econazole, ketoconazole, miconazole and fluconazole.
10. The pharmaceutical composition of claim 1 further contained in a carrier.
11. The composition of claim 10 wherein the concentration of said peptide is at least  $10^{-12}$ M.
12. The composition of claim 11 wherein the carrier is selected from the group consisting of: saline, phosphate buffered saline, gelatin maltodextrin, cellulose, microcrystalline cellulose, methyl cellulose, carboxymethyl cellulose and hydroxymethyl cellulose with glycerin.
13. (Amended) A pharmaceutical composition for the treatment of sinusitis comprising a therapeutically effective amount of a peptide having a C-terminal sequence amino acid sequence KPV (SEQ ID NO:1) in combination with a therapeutically effective amount of a decongestant/antihistamine and a therapeutically effective amount of a fungicide.
14. (Amended) The pharmaceutical composition of claim 13 wherein the peptide is selected from the group of peptides with a C-terminal amino acid sequence consisting of: KPV

(SEQ ID NO:1), VPK-Ac-CC-Ac-KPV, HFRWGKPV (SEQ ID NO:2) and  
SYSMEHFRWGKPV (SEQ ID NO:3).

15. The composition of claim 13 wherein said fungicide is selected from the group consisting of: itraconazole, econazole, ketoconazole, miconazole and fluconazole.

16. The composition of claim 13 further comprising application of a therapeutically effective amount of an antibiotic.

17. The composition of claim 16 wherein said antibiotic is selected from the group consisting of: amoxicillin, ampicillin, azithromycin, erythromycin, nafcillin, penicillin, amoxicillin/clavulanate potassium, cefuroxime axetil, cefpodoxime proxetil, clarithromycin, and azithromycin.

18. The composition of claim 13 further comprising a therapeutically effective amount of a glucocorticosteroid.

19. The composition of claim 18 wherein said glucocorticosteroid is selected from the group consisting of: betamethasone, cortisone, dexamethasone, hydrocortisone, methylprednisone, prednisone, triamcinolone.

20. The composition of claim 13 wherein said antihistamine/decongestant is selected from the group consisting of: pseudoephedrine, phenylephrine, phenylpropanolamine, chlorpheniramine, brompheniramine, pheniramine and loratidine.

21. The pharmaceutical composition of claim 10 further solvated in a carrier.

22. The composition of claim 21 wherein the concentration of said peptide is at least  $10^{-12}$ M.

23. The composition of claim 21 wherein the carrier is selected from the group consisting of: saline, phosphate buffered saline, gelatin maltodextrin, cellulose, microcrystalline cellulose, methyl cellulose, carboxymethyl cellulose and hydroxymethyl cellulose with glycerin.
24. (Amended) A method for the treatment of sinusitis comprising application of a pharmaceutical effective amount of a peptide having a C-terminal sequence amino acid sequence **KPV (SEQ ID NO:1)**.
25. (Amended) The method of claim 24 wherein the peptide is selected from the group with a C-terminal amino acid sequence consisting of KPV (**SEQ ID NO:1**), VPK-Ac-CC-Ac-KPV, HFRWGKPV (**SEQ ID NO:2**) and SYSMEHFRWGKPV (**SEQ ID NO:3**).
26. The method of claim 24 further comprising application of therapeutically effective amount of a fungicide.
27. The method of claim 26 wherein said fungicide is selected consisting of: itraconazole, econazole, ketoconazole, miconazole and fluconazole.
28. The method of claim 24 further comprising application of a therapeutically effective amount of an antibiotic.
29. The method of claim 28 wherein said antibiotic is selected from the group consisting of: amoxicillin, ampicillin, azithromycin, erythromycin, nafcillin, penicillin, amoxicillin/clavulanate potassium, cefuroxime axetil, cefpodoxime proxetil, clarithromycin, and azithromycin.
30. The method of claim 24 further comprising application of a therapeutically effective amount of a decongestant/antihistamine.

31. The method of claim 28 further said decongestant is selected from the group consisting of: pseudoephedrine, phenylephrine, phenylpropanolamine, chlorpheniramine, bromopheniramine, pheniramine and loratidine.

32. The method of claim 24 further comprising application of a therapeutically effective amount of a glucocorticosteroid.

33. The method of claim 32 wherein said glucocorticosteroid is selected from the group consisting of: betamethasone, cortisone, dexamethasone, hydrocortisone, methylprednisone, prednisone, triamcinolone.

34. The method of claim 24 wherein said peptide is systemically or topically applied before, during or after surgery performed to treat sinusitis.